NCT02844322 2026-02-11
BDH-WM01
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
Clinical Trials
12 trialsNCT02858804 2026-02-11
BDH-MCL01
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT00198978 2023-03-20
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Goethe University
Phase 4 Completed
NCT00199082 2022-08-19
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
Goethe University
Phase 4 Completed
NCT00430352 2017-08-14
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Hoffmann-La Roche
Phase 4 Completed
NCT01295151 2016-11-02
SWITCH
University of Leeds
Phase 4 Completed
NCT01056510 2015-06-25
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
Hoffmann-La Roche
Phase 4 Completed
NCT01358253 2014-05-20
Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
Ruijin Hospital
Phase 4 Completed
NCT01593332 2012-05-08
Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis
Mashhad University of Medical Sciences
Phase 4 Completed
NCT00199004 2010-08-23
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Johann Wolfgang Goethe University Hospital
Phase 4 Completed
NCT01124526 2010-05-17
Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
Asociacion Espanola de Hematologia y Hemoterapia
Phase 4 Completed
NCT00090038 2009-10-20
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
Biogen
Phase 4 Completed